Alikhan, Raza, Gomez, Keith, Maraveyas, Anthony, Noble, Simon ![]() Item availability restricted. |
![]() |
PDF
- Accepted Post-Print Version
Restricted to Repository staff only until 25 April 2025 due to copyright restrictions. Download (687kB) |
Official URL: https://doi.org/10.1111/bjh.19414
Abstract
A shared decision on the most appropriate agent for the treatment of cancer-associated thrombosis should consider the following factors, which should be reassessed as patients continue along their cancer care pathway: risk of bleeding; tumour site; suitability of oral medications; potential for drug–drug interactions; and patient preference and values regarding choice of drug. Continuing anticoagulation beyond 6 months in patients with cancer-associated venous thromboembolism and active cancer is recommended.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Schools > Medicine |
Publisher: | Wiley |
ISSN: | 0007-1048 |
Date of First Compliant Deposit: | 14 March 2025 |
Date of Acceptance: | 11 March 2024 |
Last Modified: | 14 Mar 2025 10:15 |
URI: | https://orca.cardiff.ac.uk/id/eprint/176004 |
Actions (repository staff only)
![]() |
Edit Item |